We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00348465
First Posted: July 4, 2006
Last Update Posted: May 22, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
New York Methodist Hospital
July 3, 2006
July 4, 2006
May 22, 2008
May 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00348465 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds
An Observational Study to Evaluate the Changes in Prostate Volume Over Time With The Use of Transrectal Ultrasound and Computed Tomography Following Permanent Prostate Brachytherapy With Iodine-125 Seeds.
The size of the prostate changes due to insertion of the radioactive seeds. We will measure the prostate size, before and after the procedure.
The prostate size will be measured using the TRUS and CT scan on days -1, 0, 1, 9, 30, and 60 days after the brachytherapy procedure.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Prostate Cancer patients
Prostate Cancer
Procedure: Brachytherapy with Iodine-125 seeds
Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
Other Name: Prostate Volume over time
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
March 2008
Not Provided

Inclusion Criteria:

  • Pathologically confirmed diagnosis of prostate cancer
  • T1-3 disease
  • PSA <20 ng/ml
  • Patient must sign a study-specific informed consent prior to enrollment.

Exclusion Criteria:

  • Patients ineligible to brachytherapy
Sexes Eligible for Study: Male
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00348465
NYM-353
Yes
Not Provided
Not Provided
New York Methodist Hospital
New York Methodist Hospital
Not Provided
Study Chair: Hani Ashamalla, MD, FCCP New York Methodist Hospital
Principal Investigator: Ewa Bieniek, MD NY Methodist Hospital
New York Methodist Hospital
May 2008